An Exploratory Study to Evaluate Biomarkers as Predictive and /or Prognostic Factors of Benefit From Randomized Phase ll Study of mFOLFOX6+Bevacizumab or mFOLFOX6+Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer
The correlation between the values of angiogenesis-related growth factors in plasma and
efficacy, and biomarkers relevant as prognostic factors or predictive factors for
sensitivity or resistance to treatment will be examined exploratively.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS)
To evaluate the values of angiogenesis-related growth factors in plasma with PFS centrally assessed
Baseline, Cycle 8, Progression Disease
No
Ichinosuke Hyodo, MD, PhD
Principal Investigator
Graduate School of Comprehensive Human Sciences, Tsukuba University, Department of Gastroenterology
Japan: Ministry of Health, Labor and Welfare of Japan
ATOM Exploratory study
NCT01834014
May 2013
Name | Location |
---|